In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Performance of the ESC 0/1-hour algorithm for rapid rule-out and rule-in of acute myocardial infarction using high-sensitivity cardiac troponin I in patients with impaired and normal renal function

Session Best Posters 3

Speaker Raphael Twerenbold

Event : ESC Congress 2017

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Coronary Artery Disease and Comorbidities
  • Session type : Best ePosters

Authors : R Twerenbold (Basel,CH), M Rubini Gimenez (Basel,CH), T Reichlin (Basel,CH), J Boeddinghaus (Basel,CH), T Nestelberger (Basel,CH), T Badertscher (Basel,CH), C Puelacher (Basel,CH), O Miro (Barcelona,ES), FJ Martin-Sanchez (Madrid,ES), B Morawiec (Barcelona,ES), S Osswald (Basel,CH), C Mueller (Basel,CH)

R. Twerenbold1 , M. Rubini Gimenez1 , T. Reichlin1 , J. Boeddinghaus1 , T. Nestelberger1 , T. Badertscher1 , C. Puelacher1 , O. Miro2 , F.J. Martin-Sanchez3 , B. Morawiec2 , S. Osswald1 , C. Mueller1 , 1University Hospital Basel - Basel - Switzerland , 2Hospital Clinic de Barcelona - Barcelona - Spain , 3Hospital Clinic San Carlos - Madrid - Spain ,

European Heart Journal ( 2017 ) 38 ( Supplement ), 465-466

Background: The European Society of Cardiology (ESC) recommends a 0/1-hour algorithm for rapid rule-out and rule-in of non-ST-segment elevation myocardial infarction (NSTEMI) using high-sensitivity cardiac troponin (hs-cTn) concentrations irrespective of renal function. Patients with impaired renal function (IRF) are at higher risk of NSTEMI and are presenting more often with elevated levels of hs-cTn even in absence of NSTEMI, which may both contribute to a different diagnostic performance of such an algorithm as compared to patients with normal renal function (NRF).

Purpose: We aimed to assess and directly compare the diagnostic performance of the 0/1-hour algorithm using hs-cTnI in patients with IRF and NRF.

Methods: In a prospective international multicentre diagnostic study enrolling 2949 patients presenting with suspected NSTEMI to the ED, hs-cTn was determined at baseline and after one hour using hs-cTnI (Architect). Patients presenting with STEMI were excluded. The final diagnosis was centrally adjudicated by two independent cardiologists based on hs-cTnT using all available data. Safety of the algorithm was quantified as the sensitivity and negative predictive value (NPV) for AMI in the rule-out zones, selectivity as the specificity and positive predictive value (PPV) for AMI in the rule-in zones and efficacy as the percentage of the overall cohort assigned to the rule-out or rule-in zone within one hour. All diagnostic performance measures were directly compared between patients with IRF (CKD-EPI GFR <60ml/min/1.73m2) and NRF.

Results: IRF was present in 445 of total 2949 patients (15%) with a median GFR of 44.7 ml/min/1.73m2 [IQR 33.7–51.7]. Prevalence of NSTEMI (total, n=472) was substantially higher in patients with IRF as compared to NRF (32% versus 13%, p<0.001). Sensitivity of rule-out for AMI (98.6% (95% CI, 95.0–99.8) versus 98.5% (95% CI, 96.5–99.5), p=0.920) was comparable between IRF and NRF while NPV (97.4% (95% CI, 90.5–99.4) versus 99.7% (95% CI, 99.2–99.9), p=0.005) was significantly reduced in IRF (Figure 1). Specificity of rule-in (84.4% (95% CI, 79.9–88.3) versus 91.7% (95% CI, 90.5–92.9), p<0.001) was lower in IRF while PPV (70.8% (95% CI, 64.8–76.2) versus 60.7% (95% CI, 57.1–64.2), p<0.001) was higher in IRF as compared to NRF. Overall efficacy (53% versus 76%, p<0.001) was substantially lower in IRF as compared to NRF.

Conclusion: While safety of the ESC 0/1-hour algorithm using hs-cTnI is high in patients with IRF and comparable to NRF, specificity and PPV of rule-in as well as overall efficacy substantially differ. Adjustments of the existing algorithm to IRF may seem warranted to improve optimal and effective triage of these high-risk patients in the ED.

Trial Registration: number, NCT00470587

Figure 1

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are